First test of experimental cancer drug shows early safety data
NCT ID NCT05514444
Summary
This first-in-human study tested the safety and dosing of a new experimental drug called MK-4464, both alone and combined with an existing immunotherapy (pembrolizumab). It involved 64 adults with advanced solid tumors that had spread and who had run out of standard treatment options. The main goal was to find a safe dose and see how the body processes the drug, while also checking for any early signs that it might help shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Amsterdam UMC, locatie VUmc ( Site 0400)
Amsterdam, North Holland, 1081HV, Netherlands
-
Hadassah Medical Center-Oncology ( Site 0302)
Jerusalem, 9112001, Israel
-
Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0401)
Amsterdam, North Holland, 1066CX, Netherlands
-
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0201)
Toronto, Ontario, M5G 2M9, Canada
-
Rambam Health Care Campus-Oncology Division ( Site 0300)
Haifa, 3109601, Israel
-
The University of Louisville, James Graham Brown Cancer Center ( Site 0100)
Louisville, Kentucky, 40245, United States
Conditions
Explore the condition pages connected to this study.